BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi T, Ishiyama K, Ohdan H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today 2013;43:1347-54. [DOI: 10.1007/s00595-012-0473-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma. Surg Today 2015;45:1513-20. [DOI: 10.1007/s00595-014-1102-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
2 Yu W, Wang W, Rong W, Wang L, Xu Q, Wu F, Liu L, Wu J. Adjuvant radiotherapy in centrally located hepatocellular carcinomas after hepatectomy with narrow margin (< 1 cm): a prospective randomized study. J Am Coll Surg. 2014;218:381-392. [PMID: 24559953 DOI: 10.1016/j.jamcollsurg.2013.11.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
3 Suenaga M, Yamada S, Fujii T, Fuchs BC, Okumura N, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Sugimoto H. A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. Onco Targets Ther. 2013;6:1805-1812. [PMID: 24363559 DOI: 10.2147/ott.s53625] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
4 Yu WB, Rao A, Vu V, Xu L, Rao JY, Wu JX. Management of centrally located hepatocellular carcinoma: Update 2016. World J Hepatol 2017; 9(13): 627-634 [PMID: 28539990 DOI: 10.4254/wjh.v9.i13.627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
5 Wang L, Chen B, Li Z, Yao X, Liu M, Rong W, Wu F, Lin S, Liu Y, Zheng Y, Li Y, Wang W, Wu J. Optimal postoperative adjuvant treatment strategy for HBV-related hepatocellular carcinoma with microvascular invasion: a propensity score analysis. Onco Targets Ther 2019;12:1237-47. [PMID: 30863091 DOI: 10.2147/OTT.S179247] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
6 Wang L, Wang W, Yao X, Rong W, Wu F, Chen B, Liu M, Lin S, Liu Y, Wu J. Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion. Oncotarget. 2017;8:79971-79981. [PMID: 29108379 DOI: 10.18632/oncotarget.20402] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
7 Kobayashi T, Aikata H, Kobayashi T, Ohdan H, Arihiro K, Chayama K. Patients with early recurrence of hepatocellular carcinoma have poor prognosis. Hepatobiliary & Pancreatic Diseases International 2017;16:279-88. [DOI: 10.1016/s1499-3872(16)60181-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kumar AM, Fredman ET, Coppa C, El-gazzaz G, Aucejo FN, Abdel-wahab M. Patterns of cancer recurrence in localized resected hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2015;14:269-74. [DOI: 10.1016/s1499-3872(15)60382-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Xu X, Chen R, Chen Q, An K, Ding L, Zhang L, Wang F, Deng Y. Efficacy of traditional herbal medicine versus transcatheter arterial chemoembolization in postsurgical patients with hepatocellular carcinoma: A retrospective study. Complement Ther Clin Pract 2021;43:101359. [PMID: 33711747 DOI: 10.1016/j.ctcp.2021.101359] [Reference Citation Analysis]
10 Shen SL, Fu SJ, Huang XQ, Chen B, Kuang M, Li SQ, Hua YP, Liang LJ, Peng BG. Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection. BMC Cancer. 2014;14:744. [PMID: 25280428 DOI: 10.1186/1471-2407-14-744] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
11 Yamashita M, Wada H, Eguchi H, Ogawa H, Yamada D, Noda T, Asaoka T, Kawamoto K, Gotoh K, Umeshita K, Doki Y, Mori M. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. Int J Oncol. 2016;49:89-98. [PMID: 27121124 DOI: 10.3892/ijo.2016.3496] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
12 Tomimaru Y, Wada H, Eguchi H, Tomokuni A, Hama N, Kawamoto K, Marubashi S, Umeshita K, Doki Y, Mori M, Wakasa K, Nagano H. Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma. Surg Today. 2015;45:1112-1120. [PMID: 25205550 DOI: 10.1007/s00595-014-1028-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
13 Zhou DY, Qin J, Huang J, Wang F, Xu GP, Lv YT, Zhang JB, Shen LM. Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models. Oncol Lett 2017;14:4078-84. [PMID: 28943915 DOI: 10.3892/ol.2017.6717] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mokutani Y, Hata T, Miyake Y, Kuroda H, Takahashi H, Haraguchi N, Nishimura J, Mizushima T, Yamamoto H, Doki Y, Mori M. Metastasis from a primary hepatic angiosarcoma to the colon: A case report and literature review. Oncol Lett 2017;13:2765-9. [PMID: 28454464 DOI: 10.3892/ol.2017.5755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Zhai XF, Liu XL, Shen F, Fan J, Ling CQ. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study. Cancer. 2018;124:2161-2168. [PMID: 29499082 DOI: 10.1002/cncr.30915] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
16 Zheng H, Yang Y, Han J, Jiang WH, Chen C, Wang MC, Gao R, Li S, Tian T, Wang J, Ma LJ, Ren H, Zhou WP. TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling. Sci Rep 2016;6:37070. [PMID: 27901021 DOI: 10.1038/srep37070] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]